



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

Meeting to commence at 9.30 am on Wednesday 19th May 2021
(via Zoom)

AGENDA

Enclosure

1. Welcome and introduction
 2. Apologies
 3. Declarations of interest
 4. Minutes of the previous meeting 1/AWMSG/0521
 5. Chairman's report
 6. AWTTTC Work Programme:
 - The All Wales Medicines Strategy Group: 18 years' experience of a National Medicines Optimisation Committee 2/AWMSG/0521
 - Appraisal of biosimilar medicines (for information) 3/AWMSG/0521
 7. Initial clinical management of adult smokers in secondary care 4/AWMSG/0521
 8. Educational pack: Material to support appropriate prescribing of hypnotics and anxiolytics across Wales (2021 update) 5/AWMSG/0521
 9. Ulipristal acetate (Esmya®): Review of Final Appraisal Recommendation (FAR) Advice No. 0716 - March 2016 6/AWMSG/0521
 10. Appraisal 1: Full Submission 7/AWMSG/0521
indacaterol/glycopyrronium/mometasone (Enerzair Breezhaler®) for maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long- acting beta2- agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year Appendices
- To protect commercial confidentiality the following appraisal will be held in private and all observers will be asked to leave the meeting**
11. Appraisal 2: Limited Submission (WPAS) 8/AWMSG/0521
Perampanel (Fycompa®) as adjunctive treatment of partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 to < 12 years of age Appendices
 12. Appraisal 3: Paediatric licence extension submission (WPAS) 9/AWMSG/0521
conestat alfa (Ruconest®) for the treatment of acute angioedema attacks in children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency Appendices

The outcome of all appraisals will be uploaded to the AWMSG website after the meeting.